Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist M, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg L, Juntas-Morales R, Chio A, Andersen P, Pradat P, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal N, Meyer T, Hanna M, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph A, Neuwirth C, Nations S, Shefner J, Turner M, Wuu J, Bennett R, Dang H, Sundgreen C, ORARIALS-01 trial team. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Neurol 2024; 23:687-699.
20.05.2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
20.05.2024
Lancet Neurol 2024; 23:687-699
Benatar Michael, Hansen Thomas, Rom Dror, Geist Marie A, Blaettler Thomas, Camu William, Kuzma-Kozakiewicz Magdalena, van den Berg Leonard H, Juntas-Morales Raul, Chio Adriano, Andersen Peter Munch, Pradat Pierre-Francois, Lange Dale J, Van Damme Philip, Mora Gabriele, Grudniak Mariusz, Elliott Matthew, Petri Susanne, Olney Nicholas, Ladha Shafeeq S, Goyal Namita A, Meyer Thomas, Hanna Michael G, Quinn Colin, Genge Angela, Zinman Lorne, Jabari Duaa, Shoesmith Christen, Ludolph Albert C., Neuwirth Christoph, Nations Sharon, Shefner Jeremy M, Turner Martin R, Wuu Joanne, Bennett Richard, Dang Hoang, Sundgreen Claus, ORARIALS-01 trial team
Weiter
